Ivermectin is better than benzyl benzoate for childhood scabies in developing countries

Area of Science:

• Dermatology
• Parasitology
• Tropical Medicine

Background:

• Scabies is a contagious skin infestation caused by the mite Sarcoptes scabiei.
• Pediatric scabies presents a significant public health challenge, particularly in developing countries.
• Topical benzyl benzoate and oral ivermectin are common treatment options.

Purpose of the Study:

• To compare the efficacy and safety of single-dose oral ivermectin versus topical benzyl benzoate for treating pediatric scabies.
• To evaluate treatment outcomes based on lesion count, itch scores, and adverse events.

Main Methods:

• An observer-blinded randomized controlled trial was conducted with 110 children (6 months to 14 years).
• Participants received either oral ivermectin (200 micro g/kg) or 10% topical benzyl benzoate.
• Outcomes were assessed at 3 weeks post-treatment, including lesion count, itch, and side effects.

Main Results:

• Both ivermectin and benzyl benzoate significantly reduced scabies lesions and itch.
• Ivermectin achieved a cure rate of 56% (24/43), while benzyl benzoate achieved 51% (19/37).
• Benzyl benzoate was associated with a higher incidence of local skin reactions (P = 0.004).

Conclusions:

• Oral ivermectin is a safe and effective treatment for pediatric scabies.
• Ivermectin offers additional antiparasitic benefits and is recommended over benzyl benzoate in developing countries.
• Both treatments demonstrated significant efficacy, but ivermectin showed a better safety profile regarding skin reactions.